Sorrento Therapeutics, Inc. Received and Rejected Unsolicited All Cash Acquisition Proposal

November 25, 2019 sandiegobiotech News Comments Off on Sorrento Therapeutics, Inc. Received and Rejected Unsolicited All Cash Acquisition Proposal
Sorrento Therapeutics, Inc. Received and Rejected Unsolicited All Cash Acquisition Proposal
/

SAN DIEGO, Nov. 25, 2019 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento” or the ?Company?), confirmed today that on November 23, 2019, it received an unsolicited, non-binding term sheet proposal submitted by two biopharmaceutical companies, to acquire all of the issued and outstanding shares of the Company for between $3.00 and $5.00 per share in cash.

Related Articles

No Picture
News

?Sorrento to Present New Data on Advanced Immunotherapies at Multiple Upcoming Scientific Conferences

November 6, 2019 sandiegobiotech News Comments Off on ?Sorrento to Present New Data on Advanced Immunotherapies at Multiple Upcoming Scientific Conferences

SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”), announced today that Dr. Henry Ji, Chairman and CEO, and members of Sorrento?s research team will participate in upcoming industry conferences in the… […]

No Picture
News

Sorrento Receives FDA Authorization to Start Phase 1 Clinical Trial of Proprietary, “Off-the-Shelf”, Allogeneic anti-CD38 DAR-T (Dimeric Antigen Receptor-T) Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma

August 2, 2021 sandiegobiotech News Comments Off on Sorrento Receives FDA Authorization to Start Phase 1 Clinical Trial of Proprietary, “Off-the-Shelf”, Allogeneic anti-CD38 DAR-T (Dimeric Antigen Receptor-T) Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma

SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that the FDA has authorized Sorrento’s IND application for the Phase 1 clinical testing of its allogeneic anti-CD38 Dimeric Antigen Receptor (DAR) – T Cell therapy for relapsed or refractory multiple myeloma. The… Click here to view original post… […]